Lee, H.C.Ramasamy, K.Macro, M.Davies, F.E.Abonour, R.van Rhee, F.Hungria, V.T.Puig, N.Ren, K.Silar, J.Enwemadu, V.Cherepanov, D.Stull, D.M.Leleu, X.2023-08-142023-08-142022-06-23Lee HC, Ramasamy K, Macro M, et al. P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY). Hemasphere. 2022;6(Suppl ):815-816. Published 2022 Jun 23. doi:10.1097/01.HS9.0000846568.99304.59https://hdl.handle.net/1805/34893Results from INSURE, a pooled, global analysis of 3 observational studies, show that the effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) used to treat relapsed/refractory multiple myeloma (RRMM) in routine clinical practice is comparable to its efficacy seen in the TOURMALINE-MM1 trial (median progression-free survival [PFS], 19.9 vs 20.6 months [mos]), with no new safety concerns (Leleu ASH 2021 #2701). Data on effectiveness outcomes following retreatment with agents used in earlier lines of therapy (LoTs) are limited, but may be of particular value for MM pts previously treated with lenalidomide (LEN) or proteosome inhibitors (PIs).en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalIxazomib-lenalidomide-dexamethasone (IRd)Relapsed/refractory multiple myeloma (RRMM)Lines of therapy (LoTs)Lenalidomide (LEN)Proteosome inhibitors (PIsArticle